Remicade drives Mitsubishi Tanabe's nine-month growth
This article was originally published in Scrip
Executive Summary
The TNF-targeting antibody Remicade (infliximab) was again the star performer for Mitsubishi Tanabe Pharma (MTP) in the third quarter, helping the Japanese firm overcome lower sales for a number of older prescription drugs.